cytosine and Respiratory Tract Neoplasms

cytosine has been researched along with Respiratory Tract Neoplasms in 20 studies

Respiratory Tract Neoplasms: New abnormal growth of tissue in the RESPIRATORY SYSTEM.

Research

Studies (20)

Authors

Clinical Trials (2)

Trial Overview

Trial Outcomes

12-month Change in Voice Handicap Index (VHI) Score

"Voice Handicap Index. This scale rates a patient's perception of voice related handicap in the domains of functional, physical, and emotional. There are 10 questions for each domain. Each question is rated by the subject on a 5-point scale, never =0, almost never =1, sometimes =2, almost always =3, always =4). A lower total score or domain score indicates improved, or less, voice handicap. Thus, the maximum total score is 4 X 30 = 120. For each domain, the maximum score is 4 X 10 = 40. Scores of 0 are the lowest possible score. In the paper we say that the Maximum score is 100, but obviously is it actually 120. Complete scale = 0-120.~Lower score indicates improved perceived voice-realted quality of life." (NCT00205374)
Timeframe: 2 months, and 12 months

Change in Papilloma Severity

"Derkay Severity Score. Minimum Score is Zero. Maximum score is 86. Treatment of RRP with cidofovir injection will be considered efficacious if drug group patients experience clinically or statistically significant changes in papilloma severity and inter-surgery time intervals (relative to pre-treatment assessments), when compared with placebo group patients.~The scale rates - Voice (normal 0, abnormal 1, aphonic 2) Stridor (absent 0, present with activity 1, present at rest 2) Urgency of the intervention (scheduled 0, elective 1, urgent 2, emergent 3) Respiratory distress (none 0, mild 1, mod 2, severe 3, extreme 4).~For multiple anatomical sites (18 or more) in the upper airway, left and right sides, lesions are rated as 0=none, 1=surface lesion, 2=raised lesion, and 3=bulky lesion).~A higher rating value indicates more advanced disease and a worse outcome." (NCT00205374)
Timeframe: Baseline, 2 months, and 12 months

The Primary Activity Variable Was the Recurrence of Recurrent Respiratory Papillomatosis (RRP) in Bevacizumab Treated and the Un-treated Vocal Fold in the Same Patient During and at the End of the 6-month Treatment Period.

Prior to each treatment,the area of reappearance of disease was measured and the % change from baseline was calculated. The change was then added to the % change from the previous treatment to generate a cumulative total % change of reappearance of RRP from baseline. The additive nature of this parameter resulted in % greater than 100% if the area of vocal fold affected by the RRP increased over the baseline measurement. (NCT01020747)
Timeframe: 6 months

Reviews

7 reviews available for cytosine and Respiratory Tract Neoplasms

Trials

2 trials available for cytosine and Respiratory Tract Neoplasms

Other Studies

11 other studies available for cytosine and Respiratory Tract Neoplasms